Kala Bio (KALA) Assets (2016 - 2026)
Kala Bio (KALA) posted Assets of $12.3 million for Q1 2026, up 29.8% sequentially from $9.5 million in Q4 2025, and down 74.47% YoY from $48.3 million in Q1 2025.
Kala Bio (KALA) Assets (2016 - 2026) Analysis & Trends
Kala Bio has reported Assets for 11 years, with the latest figure at $12.3 million in Q1 2026.
- Quarterly Assets fell 74.47% year-over-year to $12.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.3 million (down 74.47% YoY) and the FY2025 annual result came in at $9.5 million, down 82.9% from the prior year.
- Assets rose to $12.3 million in Q1 2026 per KALA's latest filing, from $9.5 million in the prior quarter.
- Over five years, Assets peaked at $111.6 million in Q1 2022 and troughed at $9.5 million in Q4 2025.
- A 5-year average of $57.7 million and a median of $55.9 million in 2023 frame the typical range for Assets.
- The sharpest annual moves came in 2024 and 2025: Assets retreated 0.83% in 2024, then slumped 82.9% in 2025.
- Over 5 years, Assets stood at $86.8 million in 2022, then plunged by 35.56% to $55.9 million in 2023, then declined by 0.83% to $55.5 million in 2024, then plunged by 82.9% to $9.5 million in 2025, then increased by 29.8% to $12.3 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $12.3 million, $9.5 million, and $25.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - | 12.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.32 Mn |
| Dec 31, 2025 | 9.49 Mn |
| Sep 30, 2025 | 25.02 Mn |
| Jun 30, 2025 | 36.05 Mn |
| Mar 31, 2025 | 48.25 Mn |
| Dec 31, 2024 | 55.48 Mn |
| Sep 30, 2024 | 54.08 Mn |
| Jun 30, 2024 | 61.61 Mn |
| Mar 31, 2024 | 53.03 Mn |
| Dec 31, 2023 | 55.95 Mn |
| Sep 30, 2023 | 61.12 Mn |
| Jun 30, 2023 | 66.50 Mn |
| Mar 31, 2023 | 72.23 Mn |
| Dec 31, 2022 | 86.82 Mn |
| Sep 30, 2022 | 85.70 Mn |
| Jun 30, 2022 | 84.98 Mn |
| Mar 31, 2022 | 111.57 Mn |
| Dec 31, 2021 | 139.43 Mn |
| Sep 30, 2021 | 193.81 Mn |
| Jun 30, 2021 | 215.46 Mn |